Erythromycin and Valproate Interaction
Authors: Kathleen Redington, Christine Wells, Frank Petito
Journal: Annals of Internal Medicine (1992)

Letters15 May 1992Erythromycin and Valproate InteractionKathleen Redington, MD, PhD, Christine Wells, MD, Frank Petito, MDKathleen Redington, MD, PhDSearch for more papers by this author, Christine Wells, MDSearch for more papers by this author, Frank Petito, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-116-10-877_2 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the Editors:We report the case of a 38-year-old woman with an idiopathic disorder involving partial complex and generalized seizures. Magnetic resonance imaging showed minor periventricular white matter changes. The patient was receiving valproate (Depakene, Abbott Laboratories, Chicago, Illinois), 3500 mg/d (in doses of 1500 mg, 1000 mg, and 1000 mg), and clorazepate dipotassium (Tranxene, Abbott Laboratories, Chicago, Illinois) 3.75 mg four times daily. A valproate level obtained 2 months before admission was 88.8 mg/L (therapeutic level, 40 to 100 mg/L). The patient was also receiving lithium carbonate, 300 mg twice daily, for a bipolar affective disorder. One week...References1. Schmidt D. Adverse effects of valproate. Epilepsia. 1984;25:44-9. CrossrefGoogle Scholar2. Berrettini W. A case of erythromycin induced carbamazepine toxicity. J Clin Psychiatry. 1986;47:3. Google Scholar3. WroblewskiSingerWhyte BWJ. Carbamazepine-erythromycin interaction. JAMA. 1986;255:1165-7. CrossrefMedlineGoogle Scholar4. BarzaghiGattiCrema NGF. Inhibition by erythromycin of the conversion of carbamazepine to its active 10,11-epoxide metabolite. Br J Clin Pharmacol. 1987;24:836-8. CrossrefMedlineGoogle Scholar5. ZaccaraMessoriMoroni GAF. Clinical pharmacokinetics of valproic acid-1988. Clin Pharmacokinet. 1988;15:367-89. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: Kathleen Redington, MD, PhD; Christine Wells, MD; Frank Petito, MDAffiliations: The New York Hospital New York, NY 10021 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byThe effect of erythromycin and clarithromycin versus azithromycin on serum valproate concentrationValproic AcidClinically Significant Interactions with Mood StabilisersValproic AcidMedication overuse and chronic migraine: a critical review according to clinical pharmacologyValproic AcidFatal Hydrocodone Overdose in a Child: Pharmacogenetics and Drug InteractionsAbnormal alterations in the metabolic patterns of patients on valproate therapyPerspectives on interactions between antiepileptic drugs (AEDs) and antimicrobial agentsPharmacokinetics and interactions of headache medications, part II: prophylactic treatmentsReview and Comparison of Advanced-Generation Macrolides Clarithromycin and DirithromycinRecent Advances in the Pharmacologic Treatment of Bipolar IllnessDrug interaction and pharmacological considerations during anti-infective therapy in cancer patientsValproic acid interaction 15 May 1992Volume 116, Issue 10Page: 877-878KeywordsCarbonatesEpileptic seizuresErythromycinMagnetic resonance imagingMood disorders ePublished: 1 December 2008 Issue Published: 15 May 1992 PDF downloadLoading ...